InsightRX released Gemini 2026.2, an update to the model selection engine in InsightRX Nova that adds a new general adult vancomycin model, McCarthy 2026, plus CKD-EPI eGFR versions of the published models that improved with that input. McCarthy 2026 was fit on a stratified sample drawn from 549,171 patients across 304 US organizations, scales body size on fat free mass and bends the eGFR effect on clearance at 90 mL/min/1.73 m2. InsightRX reports that the release raised individual prediction accuracy from 66% to 68%, cut bias (MPE) from 1.8% to 0.9% and cut error (NRMSE) from 28% to 27% versus Gemini 2026.1.
Our readHealth systems using Gemini get the new model recommendations automatically, and InsightRX states the Hughes 2024 obesity model is now mostly selected only for patients with obesity. It also shows the vendor retraining and revalidating models on network data after deployment. The accuracy gains are vendor reported and modest.